Quote:

---

Yet somehow, even though the company itself applied to have leronlimab included in the next round of studies, RECOVER has responded to Ganesha and asked him, rather than the company itself, if he has access to results from the company's Long Covid studies. Maybe Cytodyn screwed up its application, or, more likely, RECOVER has mismanaged its application.

---

It looks like the lower level people at the NIH handling submissions are not checking a central repository of information regarding each drug to see if they already have the information.